A long-term safety study should be performed in accordance with the outline of the clinical protocol reviewed by the CPMP, which should provide data (safety – primary analysis, and descriptive efficacy) on at least 100 patients exposed to 3 treatments with BTX-A (all patients should be followed at least 30 months).